Lyell Immunopharma, led by CEO Lynn Seely, is developing next-generation cell therapies targeting large B-cell lymphoma and metastatic colorectal cancer. The company aims to improve on existing CAR therapies in a $3 billion market for lymphoma and has a novel approach for colorectal cancer. Lyell also controls its own manufacturing facility, enabling greater control over production and launch processes. These developments position Lyell as a promising player in the cell therapy space with potential for significant market impact.
The World Health Organization's Africa regional director has warned that the Ebola outbreak in the Democratic Republic of Congo poses a serious risk of spreading to neighboring countries, with confirmed cases already reported in Uganda. The outbreak ...
CEA Industries Inc. has filed a complaint against its asset manager, 10X Capital LLC, in the U.S. District Court for Delaware. The company claims the Asset Management Agreement is one-sided and unconscionable, seeking a court declaration to void the ...
Roota, a plant-based topical hair and scalp care brand, offers a roll-on serum and activator spray formulated with rosemary oil, biotin, caffeine, peptides, Redensyl, and AnaGain. The products are designed for targeted application to support the appe...
Arctech secured the world's No. 2 position in solar tracker supply for the second year running in 2025, capturing 12.1% of the global market with 16 GW shipped. The company leads the EMEA region with a 22.6% market share, dominating in Saudi Arabia a...
GRASS surged over 27% driven by optimism around an ongoing infrastructure supercycle and strong bullish sentiment from retail and large holders. The altcoin is attempting to break above a crucial resistance level at $0.46, which could lead to further...
